# Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome

> **NCT04776876** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Advanced Neuroendocrine Neoplasm
- Carcinoid Syndrome

## Interventions

- **BIOLOGICAL:** Retifanlimab
- **DRUG:** Telotristat Ethyl

## Key facts

- **NCT ID:** NCT04776876
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-01
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study will not be opening. Support was withdrawn.
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04776876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04776876, "Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04776876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*